The Biopharmaceutical Classification System (BCS) plays a pivotal role in pharmaceutical science by categorizing drugs based on their solubility and permeability characteristics. This system provides valuable insights into how a drug is likely to behave in the human body, influencing decisions in drug development and regulatory processes.
In essence, the BCS aids in the efficient design of drug formulations, helping researchers and pharmaceutical companies optimize drug delivery methods for enhanced therapeutic outcomes. By classifying drugs into four categories (Class I to IV) based on their solubility and permeability, the BCS facilitates a systematic approach to understanding and predicting drug behavior.
This classification system is particularly valuable in guiding formulation strategies, ensuring that drug formulations are tailored to maximize bioavailability and efficacy. As advancements in biopharmaceutics continue, the BCS remains a cornerstone in the pursuit of more effective and targeted drug delivery solutions, ultimately contributing to advancements in healthcare and patient well-being.
Title : Ectopically expressed olfactory receptors as an untapped family of drug targets and discovery of agonists and antagonists of OR51E1, an understudied G protein-coupled receptor
Vladlen Slepak, University of Miami Miller School of Medicine, United States
Title : Managing healthcare transformation towards personalized, preventive, predictive, participative precision medicine ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Analytical strategies for solid-state forms in drug development
Maria Cristina Gamberini, University of Modena e Reggio Emilia, Italy
Title : Understanding drug transport in plasma: The role of protein binding
Saad Tayyab, UCSI University, Malaysia
Title : Innovative development and delivery of biologics for chronic obstructive pulmonary disease
Yong Xiao Wang, Albany Medical College, United States
Title : Search for novel biomarkers and therapeutic targets for inflammatory disease
Madhav Bhatia, University of Otago, New Zealand
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model through de-sign-inspired biotech- & biopharma-driven applications and upgraded business mar-keting to secure the human healthcare and biosafety
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : Design and evaluation of exo-itc: A bilayer fibrous system for controlled exosome delivery in dermatological applications
Luis Jesus Villarreal Gomez, FCITEC - Universidad AutĂłnoma de Baja California, Mexico
Title : Abuse-deterrent dosage form technique utilizing a fusion of innovative pharmaceuticals and ion exchange resin
Bhupendra Gopalbhai Prajapati, Parul University, India
Title : Macitentan/tadalafil combination– An additional value in pharmacotherapy of pulmonary arterial hypertension
Miroslav Radenkovic, University of Belgrade, Serbia